9-[2,3-di-O-propionyl-5-O-(tert-butyldimethylsilyl)-β-D-arabinofuranosyl]adenine | 64993-39-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 9-[2,3-di-O-propionyl-5-O-(tert-butyldimethylsilyl)-β-D-arabinofuranosyl]adenine
• 英文别名: 9-[5-O-(tert-butyldimethylsilyl)-2,3-di-O-propionyl-β-D-arabinofuranosyl]adenine；9-[2,3-di-O-propionyl-5-O-(tert-butyldimethylsilyl)-beta-D-arabinofuranosyl]adenine；[(2R,3R,4S,5R)-5-(6-aminopurin-9-yl)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-propanoyloxyoxolan-3-yl] propanoate
• CAS: 64993-39-1
• 化学式: C₂₂H₃₅N₅O₆Si
• 分子量: 493.635
• InChiKey: SISPBFOMNKCSGZ-BQSVUJTJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.97
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  141
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  9-<5-O-(tert-butyldimethylsilyl)-β-D-arabinofuranosyl>adenine 以 吡啶 、 氯仿 、 水 、 碳酸氢钠 、 丙酸酐 为溶剂， 生成 9-[2,3-di-O-propionyl-5-O-(tert-butyldimethylsilyl)-β-D-arabinofuranosyl]adenine
  参考文献：
  名称：

  9-(3,5-Di-O-acyl-.beta.-D-arabinofuranosyl)adenine compounds and method

  摘要：

  9-(3,5-Di-O-酰基-.beta.-D-阿拉伯呋喃糖基)腺嘌呤化合物，其通过在每种情况下将9-(5-O-三取代硅基-2,3-二-O-酰基-.beta.-D-阿拉伯呋喃糖基)腺嘌呤化合物与四烷基铵氟化物反应而制得。这些化合物可用作抗病毒剂。这些化合物稳定且亲脂性，适用于长效和缓释注射制剂。

  公开号：

  US04048432A1

文献信息

• 9-(3-O-Acyl-.beta.-D-arabinofuranosyl)adenine compounds,
  申请人：Parke, Davis & Company

  公开号：US04055717A1

  公开（公告）日：1977-10-25

  9-(3-O-Acyl-.beta.-D-arabinofuranosyl)adenine compounds, 9-(2,3-di-O-acyl-.beta.-D-arabinofuranosyl)adenine compounds, and their production by reacting in each case the corresponding 5-silyl ether derivative with a tetraalkylammonium fluoride. The compounds are useful as antiviral agents. The compounds are water-soluble and lipophilic, thereby being adaptable to a wide variety of pharmaceutical formulations.

  9-(3-O-Acyl-.beta.-D-arabinofuranosyl)腺嘌呤化合物，9-(2,3-di-O-acyl-.beta.-D-arabinofuranosyl)腺嘌呤化合物，分别通过将相应的5-硅醚衍生物与四烷基氟化铵反应制备而成。这些化合物可用作抗病毒剂。这些化合物具有水溶性和亲脂性，因此可适用于各种药物制剂。
• Method for the production of
  申请人：Warner-Lambert Company

  公开号：US04212941A1

  公开（公告）日：1980-07-15

  9-(2-O-Acyl-.beta.-D-arabinofuranosyl)adenine compounds and their production by enzymatic removal of the 3-O-acyl and 5-O-acyl groups of a 9-(2,3-di-O-acyl-.beta.-D-arabinofuranosyl)adenine compound or a 9-(2,3,5-tri-O-acyl-.beta.-D-arabinofuranosyl)adenine compound. The monoester compounds are useful as antiviral agents. The compounds are water-soluble and lipophilic, thereby being adaptable to a wide variety of pharmaceutical formulations.

  9-(2-O-酰基-.beta.-D-阿拉伯呋喃糖基)腺嘌呤化合物及其通过酶催化去除9-(2,3-二-O-酰基-.beta.-D-阿拉伯呋喃糖基)腺嘌呤化合物或9-(2,3,5-三-O-酰基-.beta.-D-阿拉伯呋喃糖基)腺嘌呤化合物的3-O-酰基和5-O-酰基而制备。这些单酯化合物可用作抗病毒剂。这些化合物具有水溶性和亲脂性，因此适用于各种药物配方。
• 9-(2-O-Acyl-.beta.-D-arabinofuranosyl)-adenine compounds and method for
  申请人：Parke, Davis & Company

  公开号：US04055718A1

  公开（公告）日：1977-10-25

  9-(2-O-Acyl-.beta.-D-arabinofuranosyl)adenine compounds and their production by enzymatic removal of the 3-O-acyl and 5-O-acyl groups of a 9-(2,3-di-O-acyl-.beta.-D-arabinofuranosyl)adenine compound or a 9-(2,3,5-tri-O-acyl-.beta.-D-arabinofuranosyl)adenine compound. The monoester compounds are useful as antiviral agents. The compounds are watersoluble and lipophilic, thereby being adaptable to a wide variety of pharmaceutical formulations.

  9-(2-O-Acyl-.beta.-D-arabinofuranosyl)腺嘌呤化合物及其通过酶法去除9-(2,3-di-O-acyl-.beta.-D-arabinofuranosyl)腺嘌呤化合物或9-(2,3,5-tri-O-acyl-.beta.-D-arabinofuranosyl)腺嘌呤化合物的3-O-acyl和5-O-acyl基团而制备。这些单酯类化合物可用作抗病毒剂。这些化合物既可溶于水又亲油性，因此适用于各种药物制剂。
• 9-(3,5-Di-O-acyl-.beta.-D-arabinofuranosyl)adenine compounds and method
  申请人：Parke, Davis & Company

  公开号：US04048432A1

  公开（公告）日：1977-09-13

  9-(3,5-Di-O-acyl-.beta.-D-arabinofuranosyl)adenine compounds and their production by reacting in each case a 9-(5-O-tri-substituted-silyl-2,3-di-O-acyl-.beta.-D-arabinofuranosyl)adeni ne compound with a tetraalkylammonium fluoride. The compounds are useful as antiviral agents. The compounds are stable and being lipophilic are adaptable to long-acting and depot injectable pharmaceutical formulation.

  9-(3,5-二-O-酰基-β-D-阿拉伯呋喃糖基)腺嘌呤化合物及其制备方法，通过将9-(5-O-三取代硅基-2,3-二-O-酰基-β-D-阿拉伯呋喃糖基)腺嘌呤化合物与四烷基铵氟化物反应制备而成。这些化合物可用作抗病毒剂。这些化合物稳定，并且由于是亲脂性的，因此适用于长效和缓释注射制剂的配方。